期刊文献+

LRP基因多态性和BCHE-K变异与阿尔茨海默病的相关性研究

Relationship between the polymorphism of low-density lipoprotein receptor-related protein gene,butyrylcholineste-rase-K variant and Alzheimer′s disease
下载PDF
导出
摘要 目的探讨中国汉族人低密度脂蛋白受体相关蛋白(LRP)基因多态性、丁基胆碱酯酶基因K(BCHE-K)变异与阿尔茨海默病(AD)的相关情况。方法应用聚合酶链反应-限制性片段长度多态性(PCR-RFLP)及等位基因特异-聚合酶链反应(AS-PCR)方法,观察了67例AD患者和77例正常人LRP基因和BCHE-K变异基因多态性的分布,并进行关联分析。结果AD患者LRP基因C/C纯合子基因型频率(88.1%)及等位基因C频率(94.0%)均高于对照组(P<0.05),AD患者BCHE-K变异与对照组比较均无显著性差异。结论LRP基因多态性与AD发病可能相关;BCHE-K变异与AD发病无明显相关性。 Objective To explore the relationship between low-density lipoprotein receptor-related protein (LRP) gene polymorphism, butyrylcholinesterase K(BCHE-K) variant and Alzheimer' s disease (AD) in Chinese. Methods The gene polymorphisms of LRP were examined in 67 cases of AD and 77 controls by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) methods, and BCHE-K variant was detected by allele-specific single step polymerase chain reaction amplification technique. Results The frequencies of C/C homozygote (88.1% ) and C allele (94.0%) in AD group were significantly higher than those in control group(72.7% and 85.1% respectively). There was no significant difference of BCHE-K variant between two groups. Conclusions LRP gene polymorphism may be related to AD in Chinese patients with AD. No apparant association between BCHE-K variant and AD is found, and BCHE-K variant does not confer a risk for AD.
出处 《实用老年医学》 CAS 2009年第2期132-134,共3页 Practical Geriatrics
关键词 阿尔茨海默病 低密度脂蛋白受体相关蛋白基因 丁基胆碱酯酶基因K Alzheimer' s disease low-density lipoprotein receptor-related protein gene butyrylcholinesterase-K
  • 相关文献

参考文献9

  • 1Haasl RJ, Ahmadi MR, Meethal SV, et al. A luteinizing hormone receptor intronic variant is significantly associated with decreased risk of Alzheimer's disease in males carrying an apolipoprotein E epsilon4 allele [ J ]. BMC Med Genet, 2008,9:37.
  • 2Lane R, Feldman HH, Meyer J, et al. Synergistic effect of apolipoprotein E epsilon4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's disease [ J ]. Pharmacogenet Genomics, 2008, 18 ( 4 ) : 289 -298.
  • 3Winblad B, Palmer K, Kivipelto M, et al. Mild cognitive impairment-beyond controversies, towards a consensus : report of the international working group on mild cognitive impairment [ J ]. J Intern Med, 2004,256 ( 3 ) :240-246.
  • 4Hollenbach E, Ackermann S, tion of an association between Hyman BT, et al. Confirmaa polymorphism in exon 3 of the low-density lipoprotein receptor-related protein gene and Alzheimer' s disease [ J ]. Neurology, 1998, 50 (6) : 1905-1907.
  • 5Wiebusch H, Poirier J, Sevigny P, et al. Further evidence for a synergistic association between APOE ε4 and BCHE-K in confirmed Alzheimer' s disease [ J ]. Hum Genet, 1999, 104(2) :158-163.
  • 6李国荣,朱婉儿.阿尔茨海默病早期诊断和治疗的研究进展[J].实用老年医学,2007,21(2):131-133. 被引量:8
  • 7Yoon IS, Chen E, Busse T, et al. Low-density lipoprotein receptor-related protein promotes amyloid precursor protein trafficking to lipid rafts in the endocytic pathway [ J ]. FASEB J, 2007,21 ( 11 ) :2742-2752.
  • 8Diamant S, Podoly E, Friedler A, et al. Butyrylcholinesterase attenuates amyloid fibril formation in vitro[ J]. Proc Natl Acad Sci USA, 2006,103 ( 23 ) : 8628-8633.
  • 9Calderon-Margalit R, Adler B, Abramson JH, et al. Butyrylcholinesterase activity, cardiovascular risk factors, and mortality in middle-aged and elderly men and women in Jerusalem[ J]. Clin Chem,2006,52(5 ) :845-852.

二级参考文献28

  • 1Rusinek H,Endo Y,De Santi S,et al.Atrophy rate in medial temporal lobe during progression of Alzheimer disease[J].Neurology,2004,63(12):2354-2359.
  • 2Rodrigue KM,Raz N.Shrinkage of the entorhinal cortex over five years predicts memory performance in healthy adults[J].J Neurosci,2004,63(12):956-963.
  • 3Kantarci K,Jack CR Jr.Quantitative magnetic resonance techniques as surrogate markers of Alzheimer's disease[J].NeuroRx,2004,1 (2):196-205.
  • 4Silverman DH,Small GW,Chang CY,et al.Positron emission tomography in evaluation of dementia:regional brain metabolism and longterm outcome[J].JAMA,2001,286(17):2120-2127.
  • 5Klunk WE,Engler H,Nordberg A,et al.Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B[J].Ann Neurnl,2004,55(3):306-319.
  • 6Nordberg A.PET imaging of amyloid in Alzheimer's disease[J].Lancet Neurol,2004,3(9):519-527.
  • 7Walsh DM,Klyubin I,Fadeeva JV,et al.Naturally secreted oligomers of amloid beta progein potently inhibit hippocampal long-term potentiation in vivo[J].Nature,2002,416(6880):535-539.
  • 8Brenclza RP,Bacskai BJ,Cirrito JR,et al.Anti-Abeta antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice[J].J Clin Invest,2005,115 (2):428-433.
  • 9Bayer AJ,Bullock R,Jones RW,et al.Evaluation of the safety and immunogenicity of syntbetic Abeta42(AN1792) in patients with AD[J].Neurology,2005,64(1):94-101.
  • 10Orgogozo JM,Gilman S,Dartigues JF,et al.Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization[J].Neurology,2003,61 (1):46-54.

共引文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部